Antibiotic teicoplanin tested for stubborn gut infection

NCT ID NCT04003818

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested the antibiotic teicoplanin (taken by mouth twice daily for 7 to 14 days) in 50 adults hospitalized with C. difficile infection causing diarrhea and colitis. The goal was to see if it could stop diarrhea and prevent it from coming back. The trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Teicoplanin (an antibiotic taken by mouth)

What this could lead to

If successful, this could show that teicoplanin is a safe and effective option for treating C. difficile diarrhea and colitis.

What could go wrong

The trial was terminated early with only 50 participants planned, so results are limited. It is a phase 4 study, meaning the drug is already approved, but its effectiveness for this specific use is still being explored.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLOSTRIDIUM DIFFICILE INFECTION-ASSOCIATED DIARRHEA AND COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Clostridium difficile colitis colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • investigational site CHINA

    China, China